GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (HKSE:00460) » Definitions » Cash Flow from Investing

Sihuan Pharmaceutical Holdings Group (HKSE:00460) Cash Flow from Investing : HK$186 Mil (TTM As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Sihuan Pharmaceutical Holdings Group Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the six months ended in Dec. 2023, Sihuan Pharmaceutical Holdings Group spent HK$56 Mil on purchasing property, plant, equipment. It gained HK$15 Mil from selling property, plant, and equipment. It spent HK$0 Mil on purchasing business. It gained HK$6 Mil from selling business. It spent HK$10,077 Mil on purchasing investments. It gained HK$10,283 Mil from selling investments. It paid HK$99Mil for net Intangibles purchase and sale. And it received HK$5 Mil from other investing activities. In all, Sihuan Pharmaceutical Holdings Group gained HK$76 Mil on investment activities in financial market and operating subsidiaries for the six months ended in Dec. 2023.


Sihuan Pharmaceutical Holdings Group Cash Flow from Investing Historical Data

The historical data trend for Sihuan Pharmaceutical Holdings Group's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sihuan Pharmaceutical Holdings Group Cash Flow from Investing Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 614.20 -1,096.26 -413.34 -1,855.00 185.81

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 682.99 -553.78 -1,327.43 109.77 76.04

Sihuan Pharmaceutical Holdings Group Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Sihuan Pharmaceutical Holdings Group's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Sihuan Pharmaceutical Holdings Group's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$186 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sihuan Pharmaceutical Holdings Group  (HKSE:00460) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Sihuan Pharmaceutical Holdings Group's purchase of property, plant, equipment for the six months ended in Dec. 2023 was HK$-56 Mil. It means Sihuan Pharmaceutical Holdings Group spent HK$56 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Sihuan Pharmaceutical Holdings Group's sale of property, plant, equipment for the six months ended in Dec. 2023 was HK$15 Mil. It means Sihuan Pharmaceutical Holdings Group gained HK$15 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Sihuan Pharmaceutical Holdings Group's purchase of business for the six months ended in Dec. 2023 was HK$0 Mil. It means Sihuan Pharmaceutical Holdings Group spent HK$0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Sihuan Pharmaceutical Holdings Group's sale of business for the six months ended in Dec. 2023 was HK$6 Mil. It means Sihuan Pharmaceutical Holdings Group gained HK$6 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Sihuan Pharmaceutical Holdings Group's purchase of investment for the six months ended in Dec. 2023 was HK$-10,077 Mil. It means Sihuan Pharmaceutical Holdings Group spent {stock_data.stock.currency_symbol}}10,077 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Sihuan Pharmaceutical Holdings Group's sale of investment for the six months ended in Dec. 2023 was HK$10,283 Mil. It means Sihuan Pharmaceutical Holdings Group gained HK$10,283 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Sihuan Pharmaceutical Holdings Group's net Intangibles purchase and sale for the six months ended in Dec. 2023 was HK$-99 Mil. It means Sihuan Pharmaceutical Holdings Group paid HK$99 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Sihuan Pharmaceutical Holdings Group's cash from discontinued investing activities for the six months ended in Dec. 2023 was 0 Mil. It means Sihuan Pharmaceutical Holdings Group paid HK$0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Sihuan Pharmaceutical Holdings Group's cash from other investing activities for the six months ended in Dec. 2023 was HK$5 Mil. It means Sihuan Pharmaceutical Holdings Group received HK$5 Mil from other investing activities.


Sihuan Pharmaceutical Holdings Group Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Sihuan Pharmaceutical Holdings Group's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Sihuan Pharmaceutical Holdings Group (HKSE:00460) Business Description

Traded in Other Exchanges
Address
Zhubang 2000 Business Centre, 22nd Floor, Building 4, West Balizhuang, Chaoyang District, Beijing, CHN, 100025
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Digestive System, Anti-Infective, metabolism, Respiratory, Neurology, and Others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others to provide non- or minimally invasive medical aesthetics comprehensive solutions; the innovative medicine and other medicine segments; and the generic medicine segment.
Executives
Che Fengsheng 2201 Interest of corporation controlled by you
Guo Weicheng 2201 Interest of corporation controlled by you
Meng Xianhui 2201 Interest of corporation controlled by you
Zhang Jionglong 2201 Interest of corporation controlled by you
Mingyao Capital Limited 2401 A concert party to an agreement to buy shares
Network Victory Limited 2401 A concert party to an agreement to buy shares
Proper Process International Limited 2401 A concert party to an agreement to buy shares
Successmax Global Holdings Limited 2101 Beneficial owner
Victory Faith International Limited 2401 A concert party to an agreement to buy shares
Ubs Tc (jersey) Ltd 2301 Trustee
Ubs Trustees (cayman) Ltd. 2301 Trustee
Smart Top Overseas Limited 2501 Other
Plenty Gold Enterprises Limited 2307 Founder of a discretionary trust who can infl

Sihuan Pharmaceutical Holdings Group (HKSE:00460) Headlines

No Headlines